

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
6 July 2006 (06.07.2006)

PCT

(10) International Publication Number
WO 2006/071342 A3

(51) International Patent Classification:

A61K 31/525 (2006.01) A61K 31/34 (2006.01)
A61K 31/44 (2006.01) A61K 31/22 (2006.01)
A61K 31/355 (2006.01)

(21) International Application Number:

PCT/US2005/038227

(22) International Filing Date: 20 October 2005 (20.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

11/021,282 22 December 2004 (22.12.2004) US

(71) Applicant (for all designated States except US):
DRUGTECH CORPORATION [US/US]; 300 Delaware
Avenue - Suite 1270, Wilmington, DE 19801 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BORTZ, Jonathan,**
David [US/US]; 8117 Stanford Avenue, St. Louis, MO
63130 (US). **KIRSCHNER, Mitchell, I.** [US/US]; 7235
Creveling Drive, St. Louis, MI 63130 (US). **HERMELIN,**

Marc, S. [US/US]; 791 Bismark, Glendale, MO 63122
(US). **HERMELIN, David, S.** [US/US]; Mevo Yoram 5,
Jerusalem, IL 92346 (US).

(74) Agent: **WACHTER, Mark, F.**; Blackwell Sanders Peper
Martin, LLP, 720 Olive Street, Suite 2400, St. Louis, MO
63101 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY,
MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CARDIOVASCULAR COMPOSITIONS

METABOLIC PATHWAY OF THE ESSENTIAL FATTY ACIDS

Omega-6 PUFAs

Linoleic Acid (LA)

 Δ - A6Desaturase

Gamma-Linolenic Acid (GLA)

Arachidonic Acid

Omega-6 derived Eicosanoids

Thromboxane A₂, proaggregatoryLeukotriene B₄, promotes white
blood cell adhesion

Omega-3 PUFAs

Alpha-Linolenic Acid (ALA)

 Δ - A6Desaturase

Eicosapentaenoic Acid (EPA)

Docosahexaenoic Acid (DHA)

Omega-3 derived Eicosanoids

Prostacyclin (PGI₃), antiaggregatoryThromboxane A₃, less activeLeukotriene B₅, 5% to 10% as activeas Leukotriene B₄

(57) **Abstract:** Compositions that promote and/or maintain cardiovascular health through the treatment of one or more cardiovascular diseases are provided. Also provided are methods for using compositions that promote and/or maintain cardiovascular health through the prevention, stabilization, reversal and/or treatment of coronary artery disease and/or cerebrovascular disease. Such compositions may be used independently to promote and/or maintain cardiovascular health or used in combination with one or more other compositions used in the treatment of various other disease states common to aging and/or a health deteriorating condition.

WO 2006/071342 A3



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

9 August 2007